MA28088A1 - Molecules se liant a nogo-a et utilisation pharmaceutique de celles-ci - Google Patents

Molecules se liant a nogo-a et utilisation pharmaceutique de celles-ci

Info

Publication number
MA28088A1
MA28088A1 MA28921A MA28921A MA28088A1 MA 28088 A1 MA28088 A1 MA 28088A1 MA 28921 A MA28921 A MA 28921A MA 28921 A MA28921 A MA 28921A MA 28088 A1 MA28088 A1 MA 28088A1
Authority
MA
Morocco
Prior art keywords
ser
val
thr
pro
leu
Prior art date
Application number
MA28921A
Other languages
English (en)
Inventor
Carmen Barske
Stefan Frentzel
Anis Khusro Mir
Martin E Schwab
Alessandra Vitaliti
Original Assignee
Novartis Ag
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Univ Zuerich filed Critical Novartis Ag
Publication of MA28088A1 publication Critical patent/MA28088A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

130 135 140 Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gin Thr Asn Ser Met Val Thr 145 150 155 160 Leu Gly cys Leu Val Lys Gly Tyr Phe Pro Grd Pro Val Thr Val Thi 165 170 175 Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val 180 185 190 Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Pro Ser 195 200 205 Ser Thr Trp Pro Ser Glu Thr Val Thr Cys Asn Val Ala 210 215 220 <210> 3 <211> 238 <212> PRT <213> Mus musculus <220> <221> CHAIN
MA28921A 2003-09-19 2006-04-07 Molecules se liant a nogo-a et utilisation pharmaceutique de celles-ci MA28088A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0321997.9A GB0321997D0 (en) 2003-09-19 2003-09-19 Organic compound

Publications (1)

Publication Number Publication Date
MA28088A1 true MA28088A1 (fr) 2006-08-01

Family

ID=29266310

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28921A MA28088A1 (fr) 2003-09-19 2006-04-07 Molecules se liant a nogo-a et utilisation pharmaceutique de celles-ci

Country Status (25)

Country Link
US (2) US20090181023A1 (fr)
EP (3) EP1668033A2 (fr)
JP (1) JP2007527232A (fr)
KR (1) KR20060119982A (fr)
CN (1) CN1878792A (fr)
AR (1) AR045671A1 (fr)
AU (2) AU2004274164B2 (fr)
BR (1) BRPI0414174B8 (fr)
CA (1) CA2538725C (fr)
CO (1) CO5680457A2 (fr)
EC (1) ECSP066431A (fr)
GB (1) GB0321997D0 (fr)
IL (2) IL174145A (fr)
IS (1) IS8404A (fr)
MA (1) MA28088A1 (fr)
MY (2) MY161068A (fr)
NO (1) NO20061678L (fr)
NZ (1) NZ545679A (fr)
PE (1) PE20050949A1 (fr)
RU (1) RU2380377C2 (fr)
SG (1) SG146660A1 (fr)
TN (1) TNSN06085A1 (fr)
TW (1) TWI372060B (fr)
WO (1) WO2005028508A2 (fr)
ZA (1) ZA200601842B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1711530T3 (da) * 2003-12-22 2009-12-14 Glaxo Group Ltd Nogo-A-neutraliserende immunoglobuliner til behandling af neurologiske sygdomme
US20090137484A1 (en) * 2004-12-01 2009-05-28 National University Of Singapore Neuronal Network-Interacting Peptide
WO2007003421A2 (fr) * 2005-07-05 2007-01-11 Glaxo Group Limited Immunoglobulines
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
JP5698534B2 (ja) * 2007-11-02 2015-04-08 ノバルティス アーゲー 改良されたｎｏｇｏ−ａ結合分子およびその医薬的使用
US8828390B2 (en) 2010-07-09 2014-09-09 Universitat Zurich Uses of NOGO-A inhibitors and related methods
KR20150036398A (ko) 2012-07-05 2015-04-07 글락소 그룹 리미티드 근육위축가쪽경화증의 치료에서의 항­ｎｏｇｏ­ａ 항체의 최적 투여 섭생
CN113527462B (zh) * 2020-04-22 2023-05-23 北京大学 一种具有镇痛作用的小分子肽及其特异性抗体
CN114470197B (zh) * 2022-02-16 2023-10-03 天津长和生物技术有限公司 低氧培养的hUCMSC联合NogoA抗体在脊髓损伤治疗中的应用
WO2024041450A1 (fr) * 2022-08-22 2024-02-29 舒泰神（北京）生物制药股份有限公司 Anticorps pour reconnaître de manière spécifique nogo-a et son utilisation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308573D0 (en) 1983-03-29 1983-05-05 British Nuclear Fuels Ltd Filament impregnating/coating
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1988001649A1 (fr) 1986-09-02 1988-03-10 Genex Corporation Molecules de liaison de chaines de polypeptide simples
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
BR9007115A (pt) 1989-02-13 1991-11-26 Schering Ag Novo trombolitico
EP2264174A3 (fr) * 1998-07-22 2012-03-07 SmithKline Beecham Limited Protéine semblable à la protéine spécifique des cellules neuroendocriniennes et ADNc codant
ES2341842T3 (es) * 2000-01-12 2010-06-29 Yale University Bloqueo del crecimiento axonal mediado por el receptor de nogo.
DK1461300T3 (da) * 2001-11-30 2011-10-24 Biogen Idec Inc Antistoffer mod kemotaktiske monocytproteiner
GB0228832D0 (en) * 2002-12-10 2003-01-15 Novartis Ag Organic compound
DK1711530T3 (da) * 2003-12-22 2009-12-14 Glaxo Group Ltd Nogo-A-neutraliserende immunoglobuliner til behandling af neurologiske sygdomme

Also Published As

Publication number Publication date
CN1878792A (zh) 2006-12-13
AR045671A1 (es) 2005-11-02
CA2538725C (fr) 2010-12-21
TW200517123A (en) 2005-06-01
ZA200601842B (en) 2007-09-26
EP1668033A2 (fr) 2006-06-14
US20110008334A1 (en) 2011-01-13
CO5680457A2 (es) 2006-09-29
CA2538725A1 (fr) 2005-03-31
IL203007A0 (en) 2011-08-01
MY161068A (en) 2017-04-14
JP2007527232A (ja) 2007-09-27
IL174145A0 (en) 2006-08-01
BRPI0414174B1 (pt) 2019-06-04
RU2380377C2 (ru) 2010-01-27
AU2009200237B2 (en) 2011-05-19
BRPI0414174A (pt) 2006-10-31
IL203007A (en) 2013-10-31
AU2004274164A1 (en) 2005-03-31
RU2006112849A (ru) 2007-12-20
EP2423225A3 (fr) 2013-03-20
BRPI0414174B8 (pt) 2021-05-25
GB0321997D0 (en) 2003-10-22
WO2005028508A2 (fr) 2005-03-31
NO20061678L (no) 2006-06-16
KR20060119982A (ko) 2006-11-24
WO2005028508A3 (fr) 2005-07-07
TNSN06085A1 (en) 2007-10-03
PE20050949A1 (es) 2005-12-16
MY158078A (en) 2016-08-30
EP2423225A2 (fr) 2012-02-29
SG146660A1 (en) 2008-10-30
EP2248827A1 (fr) 2010-11-10
TWI372060B (en) 2012-09-11
AU2004274164B2 (en) 2009-02-05
IS8404A (is) 2006-04-10
US20090181023A1 (en) 2009-07-16
NZ545679A (en) 2009-11-27
IL174145A (en) 2010-11-30
ECSP066431A (es) 2006-09-18
AU2009200237A1 (en) 2009-02-12

Similar Documents

Publication Publication Date Title
MA28088A1 (fr) Molecules se liant a nogo-a et utilisation pharmaceutique de celles-ci
HUP0400719A2 (hu) Vegyületek és eljárások Chlamydia-fertőzés diagnosztikájára és kezelésére
FR16C1012I2 (fr) Utilisation therapeutique d&#39;anticorps anti-cs1
WO2004024097A8 (fr) Compositions et methodes de traitement de maladies de nature immune
EP3202418C0 (fr) Anticorps monoclonal anti-lag-3 cytotoxique et son utilisation dans le traitement ou la prévention d&#39;un rejet du greffon d&#39;organe et de maladies auto-immunes
EP2120938A4 (fr) Analogues de l&#39;imidazopyridine en tant que modulateurs du récepteur de cb2, utilisables pour le traitement de la douleur et des maladies respiratoires et non respiratoires
EP1567544A4 (fr) Utilisation de polypeptides hmgb permettant d&#39;accroitre des reponses immunitaires
EP1771188A4 (fr) Methodes et compositions destinees au traitement de l&#39;obesite, de maladies associees a l&#39;insuline et de l&#39;hypercholesterolemie
SE0102831D0 (sv) Anordning vid en handprotes
EP1648499A4 (fr) Peptides de liaison specifiques de l&#39;exopolysaccharide mucoide de p. aeruginosa
WO2003104986A8 (fr) Creation d&#39;interfaces utilisateurs au moyen de taches generiques
ATE410195T1 (de) Hydrokolloidzusammensetzungen
BRPI0510947A (pt) tratamento de doença respiratória
EP1422240A3 (fr) Analogues de la nociceptine
TWD111627S1 (zh) 血壓監測器
FR2865652B1 (fr) Utilisation d&#39;extraits de plantes et de molecules purifiees pour des compositions cosmetique, nutraceutique ou pharmaceutique a action amincissante lipolytique.
EP1877795A4 (fr) Profilage diagnostique d&#39;anticorps seriques
FR2915397B1 (fr) Composition pharmaceutique et/ou cosmetique contenant des principes actifs activateurs de l&#39;aconitase
PT1216007E (pt) Utilizacao de latex de borracha em combinacao com amido
ITRN20040042A1 (it) Garza chirurgica con matrice di identificazione
DK1694271T3 (da) FSH-glykosyleringsmutant
FR2882256B1 (fr) Utilisation cosmetique d&#39;au moins un tetrapeptide naturel ac-n-ser-asp-lys-pro- ou un de ses analogues en tant qu&#39;agent pour ralentir la chute des cheveux et/ou stimuler leur croissance
FR2859904B1 (fr) Perfectionnement aux dispositifs d&#39;osteosynthese de type vis, broche ou similaire
FR2894142B1 (fr) Utilisation de l&#39;association du dipeptide tyrosine-arginine et de la niacimanide en tant qu&#39;antagoniste de substance p
BR0113579A (pt) Proteìnas sintéticas modificadas por polìmero